Neurogene (NASDAQ:NGNE) Research Coverage Started at SVB Leerink

SVB Leerink assumed coverage on shares of Neurogene (NASDAQ:NGNE) in a research note released on Monday, Marketbeat.com reports. The firm issued an outperform rating and a $46.00 price target on the stock.

NGNE has been the subject of several other reports. Stifel Nicolaus started coverage on shares of Neurogene in a report on Friday, January 5th. They issued a buy rating and a $31.00 price target for the company. HC Wainwright boosted their target price on Neurogene from $45.00 to $55.00 and gave the stock a buy rating in a research report on Tuesday, March 19th. William Blair initiated coverage on Neurogene in a report on Thursday, March 21st. They issued an outperform rating and a $61.00 price target on the stock. Finally, TD Cowen initiated coverage on Neurogene in a report on Thursday, January 4th. They set an outperform rating for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of Buy and an average price target of $48.25.

Neurogene Trading Down 2.1 %

Shares of NASDAQ NGNE opened at $33.77 on Monday. The business has a 50-day moving average of $38.08. Neurogene has a 52 week low of $12.20 and a 52 week high of $53.00. The company has a market cap of $434.48 million, a P/E ratio of -2.71 and a beta of 1.26.

Hedge Funds Weigh In On Neurogene

Several institutional investors have recently modified their holdings of NGNE. Privium Fund Management UK Ltd bought a new position in Neurogene during the first quarter valued at approximately $274,000. Great Point Partners LLC bought a new position in shares of Neurogene during the 4th quarter valued at $19,268,000. Avidity Partners Management LP purchased a new position in Neurogene in the 4th quarter worth $9,036,000. Finally, BML Capital Management LLC bought a new stake in Neurogene in the fourth quarter worth $478,000. 52.37% of the stock is currently owned by institutional investors.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.